According to a new report, published by KBV research, The Global Degenerative Disc Disease Treatment Market size is expected to reach $42.5 billion by 2031, rising at a market growth of 5.3% CAGR during the forecast period.
The Oral segment generated the highest revenue in the Global Degenerative Disc Disease Treatment Market by Route of Administration in 2023; thereby, achieving a market value of $26.4 billion by 2031. Oral medications offer convenience and ease of administration compared to other routes, such as injections or topical applications. Patients can take oral medications at home or on the go without the need for specialized medical supervision, enhancing treatment adherence and patient compliance.
The NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) segment is registering a CAGR of 4.6 % during the forecast period. NSAIDs are effective in reducing pain and inflammation associated with DDD. Degenerative Disc Disease often leads to localized inflammation in the spine, causing pain due to irritation of nerves and surrounding tissues.
The Hospitals segment led the Global Degenerative Disc Disease Treatment Market by End Use in 2023; thereby, achieving a market value of $18 billion by 2031. Hospitals offer multidisciplinary care facilities where patients with complex medical conditions like DDD can access specialized services under one roof. This includes orthopedic departments, neurosurgery units, pain management clinics, physical therapy centers, and rehabilitation services, all crucial for managing various aspects of DDD.
The Physical Therapy segment is growing at a CAGR of 4.4 % during the forecast period. Physical therapy offers a non-invasive and conservative treatment option for DDD patients, emphasizing therapeutic exercises, manual techniques, and patient education to alleviate pain, improve mobility, and promote spinal health.
Full Report: https://www.kbvresearch.com/degenerative-disc-disease-treatment-market/
The North America region dominated the Global Degenerative Disc Disease Treatment Market by Region in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $16 billion by 2031. The Asia Pacific region is anticipated to grow at a CAGR of 5.9% during (2024 - 2031). Additionally, The Europe region would witness a CAGR of 5.2% during (2024 - 2031).
By Route of Administration
By Drugs
By End Use
By Treatment Type
Unique Offerings 
